A compound of Formula or a tautomer or a stereoisomeric form thereof, wherein R 1 is selected from the group consisting of -C 1-3 alkyl, -C 1-3 alkyl-F and fluoro; R 2 is selected from the group consisting of -SO 2 C 1-3 alkyl, -SO 2 cyclopropyl, -CN, -OC 1-3 alkyl, CF 3, and -SO(NCH 3)CH 3; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents each independently selected from the group consisting of halo, cyano, C 1-3 alkyl, cyclopropyl, C 1-3 alkyloxy, cyclopropyloxy, (cyclopropyl)C 1-3 alkyloxy, monohalo-C 1-3 alkyl, polyhalo-C 1-3 alkyl, monohalo-cyclopropyl, polyhalo-cyclopropyl, monohalo-C 1-3 alkyloxy, polyhalo-C 1-3 alkyloxy, monohalo-cyclopropyloxy, polyhalo-cyclopropyloxy, (C 1-3 alkyloxy)C 1-3 alkyloxy, (cyclopropyloxy)C 1-3 alkyloxy, and HC≡CCH 2 O; heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, and oxadiazolyl, each optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, cyano, C 1-3 alkyl, cyclopropyl, C 2-3 alkynyl, C 1-3 alkyloxy, cyclopropyloxy, (cyclopropyl)C 1-3 alkyloxy, monohalo-C 1-3 alkyl, polyhalo-C 1-3 alkyl, monohalo-cyclopropyl, polyhalo-cyclopropyl, monohalo-C 1-3 alkyloxy, polyhalo-C 1-3 alkyloxy, monohalo-cyclopropyloxy, polyhalo-cyclopropyloxy, (C 1-3 alkyloxy)C 1-3 alkyloxy, (cyclopropyloxy)C 1-3 alkyloxy, and HC≡CCH 2 O; R 3, R 4, R 5, and R 6 are each independently selected from the group consisting of H, fluoro, methyl and methoxy; and R 7 is hydrogen or fluoro; or a pharmaceutically acceptable addition salt or a solvate thereof. R 1 is selected from the group consisting of -C 1-3 alkyl, -C 1-3 alkyl-F and fluoro; R 2 is selected from the group consisting of -SO 2 C 1-3 alkyl, -SO 2 cyclopropyl, -CN, -OC 1-3 alkyl, CF 3, and -SO(NCH 3)CH 3; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents each independently selected from the group consisting of halo, cyano, C 1-3 alkyl, cyclopropyl, C 1-3 alkyloxy, cyclopropyloxy, (cyclopropyl)C 1-3 alkyloxy, monohalo-C 1-3 alkyl, polyhalo-C 1-3 alkyl, monohalo-cyclopropyl, polyhalo-cyclopropyl, monohalo-C 1-3 alkyloxy, polyhalo-C 1-3 alkyloxy, monohalo-cyclopropyloxy, polyhalo-cyclopropyloxy, (C 1-3 alkyloxy)C 1-3 alkyloxy, (cyclopropyloxy)C 1-3 alkyloxy, and HC≡CCH 2 O; heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, and oxadiazolyl, each optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, cyano, C 1-3 alkyl, cyclopropyl, C 2-3 alkynyl, C 1-3 alkyloxy, cyclopropyloxy, (cyclopropyl)C 1-3 alkyloxy, monohalo-C 1-3 alkyl, polyhalo-C 1-3 alkyl, monohalo-cyclopropyl, polyhalo-cyclopropyl, monohalo-C 1-3 alkyloxy, polyhalo-C 1-3 alkyloxy, monohalo-cyclopropyloxy, polyhalo-cyclopropyloxy, (C 1-3 alkyloxy)C 1-3 alkyloxy, (cyclopropyloxy)C 1-3 alkyloxy, and HC≡CCH 2 O; R 3, R 4, R 5, and R 6 are each independently selected from the group consisting of H, fluoro, methyl and methoxy; and R 7 is hydrogen or fluoro; or a pharmaceutically acceptable addition salt or a solvate thereof.